Ranexa.com – Information about Ranexa (ranolazine extended-release tablets) treatment for chronic angina for healthcare professionals, including Ranexa benefits, efficacy, safety, tolerability, and dosing

Safety profile in special patient populations

Ranexa may be an appropriate treatment option for chronic angina patients with diabetes, chronic angina patients with heart failure, and geriatric patients with chronic angina.¹

Read about safety in special patient populations

Over 1 million hours of Holter data

The electrocardiographic effects of Ranexa are based on analyses of approximately
1 million hours of continuous Holter monitoring data collected from more than 6000 patients representing an estimated 3 billion heartbeats.³

Read about the MERLIN-TIMI 36 clinical trial

Sign Up for Updates

You are now leaving Ranexa.com.

You are now leaving the Ranexa website. Gilead Sciences, Inc. provides these links as a convenience; however, Gilead does not control, review, or endorse third-party websites, and is not responsible for the content of the website you are about to enter.